<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03503786</url>
  </required_header>
  <id_info>
    <org_study_id>MITO END-3</org_study_id>
    <secondary_id>2016-004403-31</secondary_id>
    <nct_id>NCT03503786</nct_id>
  </id_info>
  <brief_title>Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial Cancer</brief_title>
  <acronym>MITO END-3</acronym>
  <official_title>MITO END-3: A Randomized Phase II Trial of Carboplatin+Paclitaxel Compared to Carboplatin+Paclitaxel+Avelumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety and activity of the Avelumab in combination with&#xD;
      Carboplatin-Paclitaxel in advanced or recurrent endometrial cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 2 randomized with a safety run-in cohort for the experimental arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>18 months from beginning of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with complete and partial responses</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>worst grade toxicity per patient</measure>
    <time_frame>evaluated every 3 weeks up to 2 years</time_frame>
    <description>according to Common Toxicity Criteria for Adverse Events v. 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in patient-reported outcome (PRO) scores of quality of life and endometrial cancer disease and treatment related symptoms from baseline</measure>
    <time_frame>up to 2 years</time_frame>
    <description>European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C-30 En-24C QOL questionnaire C-30 En-24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in patient-reported outcome (PRO) scores of symptomatic toxicities during treatment</measure>
    <time_frame>up to 2 years</time_frame>
    <description>PRO-CTCAE questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carboplatin AUC 5+Paclitaxel 175 mg/m2 q 21days for 6-8 cycles and Avelumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy and avelumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin AUC 5+ Paclitaxel 175 mg/ m2+Avelumab 10 mg/kg q 21days for 6 -8 cycles + Avelumab 10 mg/kg every 14 days until disease progression or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC 5 i.v. every 3 weeks for 6 - 8 cycles</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_label>Chemotherapy and avelumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel 175 mg/m2 i.v. every 3 weeks for 6-8 cycles</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_label>Chemotherapy and avelumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Avelumab 10 mg/kg every 3 weeks for 6-8 cycles + Avelumab 10 mg/kg every 14 days until disease progression or unacceptable toxicity</description>
    <arm_group_label>Chemotherapy and avelumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female aged at least 18 years on day of signing informed consent&#xD;
&#xD;
          2. ECOG Performance Status of 0-1&#xD;
&#xD;
          3. Patients with newly diagnosed or recurrent endometrial cancer FIGO stage III-IV and&#xD;
             histologically-confirmed (any histology except sarcoma and carcinosarcoma)&#xD;
&#xD;
          4. Patients may have received adjuvant treatment (platinum-based cytotoxic chemotherapy&#xD;
             and/or radiotherapy). Patients having received prior chemotherapy must have completed&#xD;
             their treatment at least 6 months prior to registration for protocol therapy. Patients&#xD;
             having received prior radiotherapy must have completed their treatment at least 28&#xD;
             days prior to registration for protocol therapy&#xD;
&#xD;
          5. Have measurable disease based on RECIST v1.1 criteria&#xD;
&#xD;
          6. Availability of tumor samples for biomarker analysis&#xD;
&#xD;
          7. Endometrial cancer will include all carcinomas, including endometrioid carcinoma,&#xD;
             papillary serous carcinoma, clear cell carcinoma&#xD;
&#xD;
          8. Adequate hematological function defined by absolute neutrophil count (ANC) ≥ 1500 ×&#xD;
             mm3, platelet count ≥ 100,000 × mm3, and hemoglobin ≥ 9 g/dL (may have been&#xD;
             transfused)&#xD;
&#xD;
          9. Adequate hepatic function defined by a total bilirubin level ≤ 1.5 × the upper limit&#xD;
             of normal (ULN) range and AST and ALT levels ≤ 2.5 × ULN for all subjects (or ≤ 5 x&#xD;
             ULN if liver metastases are present)&#xD;
&#xD;
         10. Adequate renal function defined by an estimated creatinine clearance ≥ 50 mL/min&#xD;
             according to the Cockcroft-Gault formula or serum creatinine ≤ 1.5 ULN (for local&#xD;
             institutional standard method)&#xD;
&#xD;
         11. Alkaline phosphatase &lt; 1.5 x ULN for the institution (if &gt; 1.5 x ULN, then alkaline&#xD;
             phosphatase liver fraction must be &lt; 1.5 ULN)&#xD;
&#xD;
         12. Be willing and able to provide written informed consent/assent for the trial&#xD;
&#xD;
         13. Females of childbearing potential must have a negative serum pregnancy test (serum&#xD;
             hCG) at screening. Women of childbearing potential are those who have not been&#xD;
             surgically sterilized or have not been free from menses for ≥1 year&#xD;
&#xD;
         14. Highly effective contraception for females if the risk of conception exists. (Note:&#xD;
             The effects of the trial drug on the developing human fetus are unknown; thus, women&#xD;
             of childbearing potential must agree to use 2 highly effective contraception, defined&#xD;
             as methods with a failure rate of less than 1 % per year). Highly effective&#xD;
             contraception is required at least 28 days prior, throughout and for at least 60 days&#xD;
             after Avelumab treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who are pregnant or lactating&#xD;
&#xD;
          2. Patients with brain metastases, except those meeting the following criteria:&#xD;
&#xD;
               -  Brain metastases that have been treated locally and are clinically stable for at&#xD;
                  least 2 weeks prior to enrollment&#xD;
&#xD;
               -  No ongoing neurological symptoms that are related to the brain localization of&#xD;
                  the disease (sequelae that are a consequence of the treatment of the brain&#xD;
                  metastases are acceptable)&#xD;
&#xD;
               -  patients must be either off steroids or on a stable or decreasing dose of &lt;10mg&#xD;
                  daily prednisone (or equivalent)&#xD;
&#xD;
          3. Prior Anticancer treatment for advanced disease and/or prior therapy with an&#xD;
             anti-PD-1, anti-PD-L1, or anti-PD-L2 agent. Previous hormonal therapy for advanced&#xD;
             disease is allowed, but treatment must be discontinued at least 28 days prior to&#xD;
             registration for protocol therapy&#xD;
&#xD;
          4. History of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of&#xD;
             partially controlled asthma)&#xD;
&#xD;
          5. Known prior severe hypersensitivity to investigational product or any component in its&#xD;
             formulations, including known severe hypersensitivity reactions to monoclonal&#xD;
             antibodies (NCI CTCAE v4.03 Grade ≥ 3)&#xD;
&#xD;
          6. Prior organ transplantation, including allogeneic stem cell transplantation&#xD;
&#xD;
          7. Significant acute or chronic infections including, among others:&#xD;
&#xD;
               -  Known history of testing positive test for human immunodeficiency virus (HIV) or&#xD;
                  known acquired immunodeficiency syndrome (AIDS)&#xD;
&#xD;
               -  Positive test for hepatitis B surface antigen and / or confirmatory hepatitis C&#xD;
                  RNA (if anti-hepatitis C antibody tested positive)&#xD;
&#xD;
               -  Evidence of interstitial lung disease or active non-infectious pneumonitis.&#xD;
&#xD;
               -  Active infection requiring systemic therapy&#xD;
&#xD;
               -  Known history of active Tuberculosis Bacillus (TB)&#xD;
&#xD;
          8. Active autoimmune disease that might deteriorate when receiving an immunostimulatory&#xD;
             agent:&#xD;
&#xD;
               -  Subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease&#xD;
                  not requiring immunosuppressive treatment are eligible&#xD;
&#xD;
               -  Subjects requiring hormone replacement with corticosteroids are eligible if the&#xD;
                  steroids are administered only for the purpose of hormonal replacement and at&#xD;
                  doses ≤ 10 mg or 10 mg equivalent prednisone per day&#xD;
&#xD;
               -  Administration of steroids through a route known to result in a minimal systemic&#xD;
                  exposure (topical, intranasal, intro-ocular, or inhalation) are acceptable&#xD;
&#xD;
          9. Persisting toxicity related to prior therapy of Grade &gt;1 NCI-CTCAE v 4.03; however,&#xD;
             alopecia and sensory neuropathy Grade ≤ 2 is acceptable&#xD;
&#xD;
         10. Another primary malignancy within the past five years (except for non-melanoma skin&#xD;
             cancer and cervical carcinoma in situ).&#xD;
&#xD;
         11. Concurrent treatment with immunosuppressive or investigational agents EXCEPT for the&#xD;
             following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g.,&#xD;
             intra-articular injection); b. Systemic corticosteroids at physiologic doses ≤ 10&#xD;
             mg/day of prednisone or equivalent; c. Steroids as premedication for hypersensitivity&#xD;
             reactions (e.g., CT scan premedication).&#xD;
&#xD;
         12. Active cardiac disease, defined as:&#xD;
&#xD;
               -  Myocardial infarction or unstable angina pectoris within 6 months of the first&#xD;
                  date of study therapy,&#xD;
&#xD;
               -  History of serious ventricular arrhythmia (i.e., ventricular tachycardia or&#xD;
                  ventricular fibrillation), high-grade atrio-ventricular block, or other cardiac&#xD;
                  arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation&#xD;
                  that is well controlled with antiarrhythmic medication); history of QT interval&#xD;
                  prolongation.&#xD;
&#xD;
               -  New York Heart Association (NYHA) Class III or greater congestive heart failure,&#xD;
                  or left ventricular ejection fraction of &lt; 40%.&#xD;
&#xD;
         13. Known alcohol or drug abuse&#xD;
&#xD;
         14. Vaccination within 4 weeks of the first dose of avelumab and while on trial is&#xD;
             prohibited except for administration of inactivated vaccines&#xD;
&#xD;
         15. Any psychiatric condition that would prohibit the understanding or rendering of&#xD;
             informed consent&#xD;
&#xD;
         16. All other significant diseases (for example, inflammatory bowel disease, uncontrolled&#xD;
             asthma), which, in the opinion of the Investigator, All other significant diseases&#xD;
             (for example, inflammatory bowel disease, uncontrolled asthma) including recent or&#xD;
             active suicidal ideation or behavior, which, in the opinion of the Investigator, may&#xD;
             increase the risk associated with study participation or study treatment&#xD;
             administration or may interfere with the interpretation of study results and, in the&#xD;
             judgment of the investigator, would make the patient inappropriate for entry into this&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandro Pignata, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gennaro Daniele, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ciro Gallo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale Senatore Antonio Perrino</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione del Piemonte per l'Oncologia</name>
      <address>
        <city>Candiolo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS San Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori</name>
      <address>
        <city>MIlano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Federico II</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Università degli studi della Campania &quot;Luigi Vanvitelli&quot;</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Silvestrini</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Giovanni Calibita Fatebenefratelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Gemelli Università Cattolica del Sacro Cuore</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 6, 2018</study_first_submitted>
  <study_first_submitted_qc>April 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2018</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD-L1 Expression</keyword>
  <keyword>advanced endometrial cancer</keyword>
  <keyword>recurrent endometrial cancer</keyword>
  <keyword>Patient reported outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Avelumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

